Jorge I. Alvarez
Cincinnati Children's Hospital Medical Center
Binding of Epstein Barr Virus EBNA2 unifies multiple sclerosis genetic mechanisms
4/15/23—3/31/28
$192,440
Montserrat C. Anguera
I3H
Role for X-Chromosome Inactivation in female-biased enhancement of immune responses to influenza
7/1/23—6/30/24
$100,000
Montserrat C. Anguera
NIH
Role for nuclear matrix proteins and DNA methylation for XCI maintenance in female lymphocytes
7/1/23—6/30/28
$370,000
Michael L. Atchison
NIH
VMD-PhD training in infectious disease-related research
7/1/22—6/30/23
$237,812
Matthew J. Atherton
Penn Vet Cancer Center
PVCC Pilot
1/1/24—12/31/25
$75,000
Stephen D. Cole
State of Minnesota
People, pets and plasmids: A One Health pathogenomic training fellowship to investigate carbapenemase-producing organisms from companion animals
4/01/23—3/31/24
$26,035
Stephen D. Cole
FDA
Companion animal and animal food diagnostic sample analysis in support of FDA Vet-LIRN activities and investigation
6/01/21—5/31/24
$90,000
Stephen D. Cole
FDA
Implementation and evaluation of two SARS-CoV-2 assays for companion animal testing to expand Vet-LIRN COVID-19 capacity
9/1/23—8/31/24
$25,000
Raimon Duran-Struuck
Asher Bio
SRA-CAR-IL2
7/4/21—7/4/24
$150,827
Maureen Griffin
PetDx
The utility of OncoK9 liquid biopsy for detection of canine insulinoma
6/26/23—6/26/28
$5,000.00
Ronald N. Harty
Fox Chase/NIH
Development of host-oriented therapeutics targeting severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
8/01/23—7/31/24
$172,308
De'Broski Herbert
NIH
Neuronal regulation of sinonasal type 2 inflammation
7/01/23—6/30/25
$275,000
Anna Kashina
USDA
Fecal metagenomic and metabolomic biomarkers as tools for chronic wasting disease
9/30/23—9/29/24
$227,274
Christopher J. Lengner
DOD/CHOP
Validation of novel drivers of juvenile polyposis syndrome
9/1/23—8/31/27
$311,254
Christopher J. Lengner
Columbia/NIH
The basis for and function of enteroendocrine lineage plasticity in the intestinal DNA damage response
4/12/23—3/31/28
$54,400
Nicola J. Mason
V Foundation—Ethos
S0W 2—Unraveling mechanisms of resistance to checkpoint inhibition in canine urothelial carcinoma
7/27/23—7/27/25
$242,150
Nicola J. Mason
NIH
Advancing the coordinating center for the canine cancer immunotherapy network
9/1/22—8/31/27
$285,688
Nicola J. Mason
NIH
Advancing allogeneic CAR-iNKT for the treatment of solid tumors through comparative oncology
9/1/22—8/31/27
$354,244
Nicola J. Mason
Sebastian Strong Foundation
B7-H3 redirected allogeneic CAR-iNKT cell therapy for the treatment of pediatric patients with osteosarcoma
9/1/23—8/31/26
$190,419
Andrew J. Modzelewski
Beckman Foundation
Leveraging the phenomenon of retrotransposon reactivation in development to improve human health and treat disease
9/1/23—8/31/27
$150,000
Andrew J. Modzelewski
Searle Foundation
From parasites to symbiotes: Leveraging retrotransposon reactivation signatures in development to better understand disease
7/1/23—6/30/26
$300,000
Lisa A. Murphy
Department of Agriculture
Regional veterinary workforce development to enhance early recognition of newly-detected, re-emerging, and foreign animal diseases
6/1/2023—5/31/2025
$95,932
Cynthia Otto
Commonwealth of Pennsylvania
Comprehensive wildlife health program for the state of Pennsylvania
7/1/2023—6/30/2024
$191,285
Ellen Puré
Capstan Therapeutics
Capstan Therapeutics sponsored research agreement year 2
9/11/23—6/30/24
$245,437
Kotaro Sasaki
NIH
Stem cell-based models for elucidating human adrenocortical development and dysfunction
8/18/23—7/31/28
$319,440
P. Jeremy Wang
NIH
Epigenetic control of spermatogonial stem cell self-renewal
6/5/23—3/31/28
$1,275,078
John H. Wolfe
CTSA/PICAB
Institutional clinical and translational science award
6/01/23—5/31/24
$27,999